Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data...
December 07, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
November 22, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
November 21, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
November 06, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth Auvelity® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth Sunosi® 3Q...
November 02, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 31, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 24, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 11, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
October 10, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right